3 Asian Stocks Estimated To Be Trading At Discounts Up To 40.9%

As global markets respond to easing geopolitical tensions and investors shift back into riskier assets, the Asian stock market presents intriguing opportunities for those seeking value. In this environment, identifying stocks that are trading below their intrinsic value can be particularly appealing, as they may offer potential for growth when market sentiment improves.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Click here to see the full list of 210 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let’s explore several standout options from the results in the screener.

Overview: PharmaResearch Co., Ltd. is a biopharmaceutical company operating primarily in South Korea, with a market capitalization of ₩3.22 billion.

Operations: The company, along with its subsidiaries, generates revenue primarily from its Pharmaceuticals segment, amounting to ₩536.29 million.

Estimated Discount To Fair Value: 40.9%

PharmaResearch is trading at 40.9% below its estimated fair value and significantly below future cash flow value by more than 20%. The company’s earnings are forecast to grow significantly over the next three years, although slower than the broader Korean market. Recent strategic moves include an exclusive supply agreement with DermaDream in Brazil and a cleared IND application for PRD-101 by the FDA, which could enhance future cash flows and support international expansion efforts.

Overview: Meitu, Inc., an investment holding company, develops and provides AI-powered products for photo, video, and design production in Mainland China and internationally, with a market cap of HK$21.27 billion.

Operations: The company’s revenue segments include an Internet Business that generated CN¥3.86 billion.

Estimated Discount To Fair Value: 31.8%

Meitu is trading at 31.8% below its fair value and significantly under its future cash flow value by more than 20%. Earnings are projected to grow significantly at 32.2% annually, surpassing the Hong Kong market’s growth rate. Despite a decrease in net income for 2025, Meitu’s share repurchase program could enhance earnings per share and net asset value. Revenue growth is expected to outpace the market at 21.9% annually, supporting an undervaluation thesis based on cash flows.

Overview: XD Inc. is an investment holding company that focuses on developing, publishing, operating, and distributing mobile and web games in Mainland China and internationally, with a market cap of HK$31.27 billion.

Operations: Revenue Segments (in millions of CN¥):

Estimated Discount To Fair Value: 38.6%

XD Inc. is trading 38.6% below its estimated fair value and significantly under its future cash flow value by over 20%, highlighting potential undervaluation based on cash flows. Despite a decision to not pay a final dividend for 2025, XD reported robust financial performance with net income nearly doubling from CNY 811.53 million to CNY 1,535.27 million year-over-year. Earnings are expected to grow at 13.4% annually, outpacing the Hong Kong market’s growth rate of 12.5%.

Next Steps

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include KOSDAQ:A214450 SEHK:1357 and SEHK:2400.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com